Expression of MTCL1 in hepatocellular carcinoma and its effect on postoperative recurrence

doi:10.3877/cma.j.issn.2095-3232.2021.06.019

Abstract

Abstract:

Objective

To investigate the expression level of microtubule cross-linking factor 1(MTCL1) in hepatocellular carcinoma (HCC) and its effect on the postoperative recurrence of HCC.

Methods

Clinicopathological data of 76 HCC patients who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-sen University from October 2015 to December 2018 were retrospectively analyzed. Among them, 66 patients were male and 10 female, aged from 27 to 68 years, with a median age of 51 years. The informed consents of all patients were obtained and the local ethical committee approval was received. The expression of MTCL1 mRNA in HCC tissues were detected by quantitative real-time PCR (QRT-PCR), Western blot and immunohistochemical staining. The relationship between MTCL1 mRNA expression and survival of patients was analyzed, and was verified by TCGA database. The migration capability of HCC cells with MTCL1 overexpressing and siRNA-silenced MTCL1 was evaluated by cell scratch test in vitro. The relative expression level of MTCL1 between two groups was compared by t test. Kaplan-Meier method andLog-rank test were performed for survival analysis.

Results

The average relative expression of MTCL1 mRNA in HCC tissues was 3.47±0.86, significantly higher than 1.38±0.25 in the adjacent tissues (t=2.36, P<0.05). The relative expression of MTCL1 protein in HCC tissues was 1.07±0.18, significantly higher than 0.64±0.04 in the adjacent tissues (t=2.64, P<0.05). Immunohistochemical staining detected that MTCL1 protein was highly expressed in HCC tissues. The 3-year tumor-free survival rate was 24.7% in MTCL1 mRNA high expression group, and 52.7% in low expression group, the 3-year tumor-free survival in low MTCL1 mRNA expression group was significantly better than that in high expression group (χ²= 9.28, P<0.05). TCGA database analysis demonstrated that the overall survival in the MTCL1 mRNA high expression group was significantly shorter than that in the low expression group (HR=1.500, P<0.05). Cell scratch test showed that the wound healing rate of MHCC97-L cells in MTCL1 overexpression group was (7.79±0.31)%, significantly higher than (3.21±0.41)% in the empty control group (t=8.89, P<0.05). The wound healing rate of Hep-G2 cells in the MTCL1-siRNA group was (9.12±0.75)%, significantly lower than (13.79±0.23)% in the negative control group (t=-5.96, P<0.05).

Conclusions

MTCL1 is highly expressed in HCC tissues, which can promote the migration of HCC cells. Patients with high expression of MTCL1 likely has high recurrence and poor prognosis.

Key words: Microtubule cross-linking factor 1, Carcinoma, hepatocellular, Cell migration, Prognosis

Guozhen Lin, Tianxing Dai, Mingbin Deng, Guoying Wang. Expression of MTCL1 in hepatocellular carcinoma and its effect on postoperative recurrence[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(06): 622-628.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2021.06.019

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2021/V10/I06/622

Figures/Tables 5

References 20

[1]	Bray F, Ferlay J, Soerjomataram I，et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6):394-424.
[2]	Ferlay J, Colombet M, Soerjomataram I，et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer，2019，144(8):1941-1953.
[3]	Mizuguchi Y, Takizawa T, Yoshida H，et al. Dysregulated miRNA in progression of hepatocellular carcinoma: a systematic review[J]. Hepatol Res，2016，46(5):391-406.
[4]	Sia D, Villanueva A, Friedman SL，et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology，2017，152(4):745-761.
[5]	Zhu H, Wu J, Shen X. Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes[J]. Scand J Gastroenterol，2017，52(2):209-215.
[6]	Khan FS, Ali I, Afridi UK，et al. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics[J]. Hepatol Int, 2017, 11(1):45-53.
[7]	Kader MA, Satake T, Yoshida M，et al. Molecular basis of the microtubule-regulating activity of microtubule crosslinkingfactor 1[J]. PLoS One, 2017, 12(8):e0182641.
[8]	Haryono SJ, Datasena IGB, Santosa WB，et al. A pilot genome-wide association study of breast cancer susceptibility loci in Indonesia[J]. Asian Pac J Cancer Prev, 2015, 16(6):2231-2235.
[9]	Wang S, Pitt JJ, Zheng Y，et al. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria[J]. Int J Cancer, 2019, 145(12):3321-3333.
[10]	Saraswat S, Rout PK, Kharche SD, et al. Molecular expression of caprine estrogen receptor gene 1 in reproductive and non-reproductive tissues[J]. Reprod Domest Anim, 2016, 51(6):1049-1054.
[11]	Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma[J]. Nat Med, 2013, 19(2):209-216.
[12]	Xu R, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11):1155-1161.
[13]	Fu C, Xu X, Lu W, et al. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma[J]. Medicine，2019, 98(42):e17412.
[14]	Su YH, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma[J]. Transl Res，2018(201):84-97.
[15]	Hyodo T, Ito S, Asano-Inami E, et al. A regulatory subunit of protein phosphatase 2A, PPP2R5E, regulates the abundance of microtubule crosslinking factor 1[J]. FEBS J，2016，283(19):3662-3671.
[16]	Sato Y, Akitsu M, Amano Y, et al. The novel PAR-1-binding protein MTCL1 has crucial roles in organizing microtubules in polarizing epithelial cells[J]. J Cell Sci，2013, 126(Pt 20):4671-4683.
[17]	Sato Y, Hayashi K, Amano Y, et al. MTCL1 crosslinks and stabilizes non-centrosomal microtubules on the Golgi membrane[J]. Nat Commun, 2014(5):5266.
[18]	Satake T, Yamashita K, Hayashi K, et al. MTCL1 plays an essential role in maintaining Purkinje neuron axon initial segment[J]. EMBO J, 2017, 36(9):1227-1242.
[19]	Ferreira LT, Logarinho E, Macedo JC, et al. SOGA1 and SOGA2/MTCL1 are CLASP-interacting proteins required for faithful chromosome segregation in human cells[J]. Chromosome Res, 2021, 29(2):159-173.
[20]	Garcia J, Lizcano F. KDM4C activity modulates cell proliferation and chromosome segregation in triple-negative breast cancer[J]. Breast Cancer, 2016(10):169-175.

参数		MTCL1 mRNA		χ²值	P值
参数		低表达	高表达	χ²值	P值
性别				0.451	0.502
	男	35	18
	女	2	3
年龄				1.118	0.290
	<60岁	32	15
	≥60岁	5	6
AFP				2.312	0.128
	<400 μg/L	20	7
	≥400 μg/L	17	14
肿瘤直径				2.449	0.118
	<5 cm	22	8
	≥5 cm	15	13
肿瘤数目				0.081	0.776
	单发	26	14
	多发	11	7
BCLC分期				4.337	0.037
	A+B期	34	14
	C期	3	7
肝癌分化程度				1.045	0.307
	高中分化	33	21
	低分化	4	0
血管侵犯				6.009	0.014
	无	34	13
	有	3	8
门静脉癌栓				6.186	0.013
	无	36	15
	有	1	6
复发				5.688	0.017
	否	24	6
	是	13	15

参数		MTCL1 mRNA		χ²值	P值
参数		低表达	高表达	χ²值	P值
性别				0.451	0.502
	男	35	18
	女	2	3
年龄				1.118	0.290
	<60岁	32	15
	≥60岁	5	6
AFP				2.312	0.128
	<400 μg/L	20	7
	≥400 μg/L	17	14
肿瘤直径				2.449	0.118
	<5 cm	22	8
	≥5 cm	15	13
肿瘤数目				0.081	0.776
	单发	26	14
	多发	11	7
BCLC分期				4.337	0.037
	A+B期	34	14
	C期	3	7
肝癌分化程度				1.045	0.307
	高中分化	33	21
	低分化	4	0
血管侵犯				6.009	0.014
	无	34	13
	有	3	8
门静脉癌栓				6.186	0.013
	无	36	15
	有	1	6
复发				5.688	0.017
	否	24	6
	是	13	15

Please choose a citation manager

Content to export